Challenges associated with long-term therapies in CLL
What are the genetic and environmental risk factors for chronic lymphoblastic leukemia (CLL)?
An inroduction to the HOVON-141 trial in patients with CLL
Overview of the RESONATE-2 clinical trial of ibrutinib as front-line therapy
Overview of 3 studies on CLL therapy: data on ibrutinib and a ROR1 inhibitor